Choriogonadotropin alfa


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : SC Anovulatory infertility; Adjunct to IVF procedures and other assisted conception techniques 250 mcg as a single dose 24-48 hr after optimal stimulation of follicular growth is achieved.
Dosage Details
Subcutaneous
Adjunct to in vitro fertilisation procedures and other assisted conception techniques, Anovulatory infertility due to hypothalamic pituitary dysfunction
Adult: 250 mcg as a single dose 24-48 hr after optimal stimulation of follicular growth is achieved.
Contraindications
Primary ovarian failure, uncontrolled thyroid or adrenal function; abnormal uterine bleeding; ovarian enlargement or cyst of unknown origin; tumours of the hypothalamus, pituitary gland, and uterus; sex hormone dependent tumours of the reproductive tract and accessory organs; ovarian, uterine, or mammary carcinoma. Post-menopausal women. Pregnancy (including ectopic pregnancy in previous 3 mth).
Special Precautions
Patient w/ active or history of thromboembolic events, patient undergoing ovarian stimulation or ovulation induction. Lactation.
Adverse Reactions
Significant: Ovarian hyperstimulation syndrome (OHSS), multiple births, ovarian enlargement, arterial thromboembolism.
Nervous: Headache, tiredness, mood changes, depression, restlessness.
GI: Nausea, vomiting, abdominal pain and distension.
Genitourinary: Ovarian cysts, ectopic pregnancy.
Others: Pain, burning, inflammation, and brusing at inj site, postoperative pain.
Parenteral/SC: X
MonitoringParameters
Monitor oestradiol levels and perform ultrasound to assess follicular development, size, and number. Perform sonographic visualisation to monitor ovulation by determining basal body temp, serum progestin level, and menstruation.
Lab Interference
May cause false positive result w/ urinary HCG during pregnancy test. May cross-react w/ gonadotropin (esp LH) radioimmunoassay.
Action
Description: Choriogonadotropin alfa, an analogue of LH, is a biosynthetic recombinant form of HCG. It binds to LH/HCG receptors of the ovarian granulosa and theca cells in the absence of an endogenous LH surge. This causes stimulation of late ovarian follicular maturation, luteinisation of ovarian follicular granulosa cells, resumption of oocyte meiosis, and initiation of rupture of preovulatory ovarian follicle.
Pharmacokinetics:
Absorption: Bioavailability: 40%. Time to peak plasma concentration: 12-24 hr.
Distribution: Distributed mainly to the gonads. Volume of distribution: 21.4 L.
Metabolism: Metabolised mainly in the kidneys.
Excretion: Via urine. Elimination half-life: Biphasic: 4 hr (initial); 29 hr (terminal).
Storage
Store between 2-8°C. Protect from light.
ATC Classification
G03GA08 - choriogonadotropin alfa ; Belongs to the class of gonadotropins. Used as ovulation stimulants.
References
Anon. Chorionic Gonadotrophin (Recombinant). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 23/02/2017.

Buckingham R (ed). Chorionic Gonadotrophin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/02/2017.

Joint Formulary Committee. Choriogonadotropin Alfa (Human Chorionic Gonadotropin). British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/02/2017.

Ovidrel Injection, Solution (EMD Soreno, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 23/02/2017.

Disclaimer: This information is independently developed by MIMS based on Choriogonadotropin alfa from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in